Merck Licenses Coley Pharma's VaxImmune for $4 Million
Filed in archive Corporate and Industrial News on April 13, 2007
Merck & Co., Inc. has licensed Coley Pharmaceutical's VaxImmune(TM) vaccine adjuvant for an upfront license fee of $4 million, and milestone fess of up to $33 million plus royalties.
VaxImmune is a proprietary Toll-like receptor 9 (TLR9) agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
VaxImmune is currently under clinical trials for various cancer, infectious disease and biowarfare applications.
Source: Coley Pharmaceutical
Photo: TLR Therapeutics, Coley Pharmaceuticals
Tags: merck license investment pharma vaximmune vaccine biotech coley vaximmune+million
Vote for Merck Licenses Coley Pharma's VaxImmune for $4 Million:
|
Rating: 9.67 out of 3 vote(s) cast.
|
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells